Stability Enhancement Using Hyaluronic Acid Gels for Delivery of Human Fetal Progenitor Tenocytes. by Grognuz, A. et al.
Cell Medicine, Vol. 8, pp. 87–97, 2016 2155-1790/16 $90.00 + .00
Printed in the USA. All rights reserved. DOI: http://dx.doi.org/10.3727/215517916X690486
Copyright Ó 2016 Cognizant, LLC. www.cognizantcommunication.com
Received September 18, 2015; final acceptance February 23, 2016. Online prepub date: January 14, 2016.
Address correspondence to Professor Lee Ann Laurent-Applegate, University Hospital of Lausanne (CHUV), Service of Plastic,  
Reconstructive and Hand Surgery, Regenerative Therapy Unit (UTR), EPCR/Croisettes 22, CH-1066 Epalinges, Switzerland.  
Tel: +41-21-314-35-10; Fax: +41-21-887-84-14; E-mail: Lee.Laurent-Applegate@chuv.ch
87
Stability Enhancement Using Hyaluronic Acid Gels for Delivery  
of Human Fetal Progenitor Tenocytes
A. Grognuz,* C. Scaletta,* A. Farron,† D. P. Pioletti,‡ W. Raffoul,* and L. A. Applegate*
*Unit of Regenerative Therapy, Service of Plastic, Reconstructive and Hand Surgery, Department of Musculoskeletal Medicine, 
University Hospital of Lausanne, Lausanne, Switzerland
†Service of Orthopaedics and Traumatology, Department of Musculoskeletal Medicine,  
University Hospital of Lausanne, Lausanne, Switzerland
‡Laboratory of Biomechanical Orthopedics, Institute of Bioengineering, EPFL, Lausanne, Switzerland
Tendon afflictions are very common, and their negative impact is high both at the workplace and in leisure 
activities. Tendinopathies are increasing in prevalence and can lead to tendon ruptures, where healing is a 
long process with outcomes that are often disappointing. Human fetal progenitor tenocytes (hFPTs) have been 
recently tested in vitro as a potential cell source to stimulate tendon regeneration. The aim of the present study 
was to compare different commercial hyaluronic acid (HA) gels, which could be used to resuspend hFPTs in 
a formulation that would allow for good delivery of the cells. No medium or growth supplement was used in 
the formulation in order to make it therapeutically dispensable. These conditions are stringent for cells, but 
surprisingly, we found that different formulations could allow a good survival for up to 3 days when stored at 
4°C (refrigerator stable). The gels must allow a good survival of the cells in parallel with a good stability of the 
preparation over time and sufficient viscosity to remain in place if deposited on a wounded location. Moreover, 
the cells must conserve their ability to attach and to proliferate. hFPTs were able to survive and to recover from 
all of the tested gels, but some products showed some advantages over others in terms of survival and viscosity. 
Finally, the Ostenil Tendon HA gel fulfilled all of the requirements and presented the best compromise between 
a good survival and sufficient rheological characteristics to create an interesting cell delivery system.
Key words: Cell therapy; Hyaluronic acid gel; Tendon healing;  
Human fetal progenitor tenocytes (hFPTs); Cell stability
INTRODUCTION
Tendon afflictions are very common, and various ana-
tomical areas are affected, including the Achilles tendon, 
various hand tendons, and the rotator cuff, all of which 
are among the major tendons exposed to injury. In the 
US alone, more than 25 million sprains and strains of 
soft tissues such as tendons and ligaments are reported 
yearly (23) with an impact that is significant both at the 
workplace and in leisure activities. Our population is 
becoming older, and aging is correlated with an increase 
in chronic degeneration of tendons, presently referred to 
as tendinopathies (7,21). Elderly people are not the only 
ones affected, and with the democratization of sport prac-
tice, tendinopathies have been increasing in younger indi-
viduals during recent decades as well (4,18).
Tendon homeostasis relies on good behavior of teno-
cytes, which are the cells responsible for the secretion of 
all extracellular matrix components and the maintenance 
of a fine balance between synthesis and catabolism of 
the extracellular matrix (11). In the case of acute load-
ings, the net balance of collagen levels is negative for up 
to 18–36 h after exercise and then becomes positive up 
to 72 h. Thereafter repeated loadings without sufficient 
rest can lead to an amplification of the collagen break-
down (15). The extracellular matrix becomes more dis-
organized and weaker, and many changes in the structure 
are detectable (14). Tendinopathies are not only pain-
ful but also make tendons more prone to ruptures (12). 
In cases of rupture, tendon healing relies on a cascade 
of events. Tenocytes have an important role as they are 
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responsible for the formation of new extracellular matrix. 
Unfortunately, the quality of the new tissue never reaches 
that of the original tissue prior to injury and scar tissue, 
and adhesions are frequent, which often leads to decreased 
mobility and reruptures (10,20,24).
Therefore, tenocytes have an important role both in 
tendinopathies and in tendon ruptures, and their modula-
tion would be very interesting to improve the outcomes 
obtained. Human fetal progenitor fibroblasts have shown 
excellent results in modulating regeneration of tissues such 
as skin toward a less fibrotic process (2,9). We recently 
tested human fetal progenitor tenocytes (hFPTs) as a 
potential cell source for tendon regeneration and showed 
that it was possible to create cell banks with very high 
numbers of cells and with respect to good manufactur-
ing practice (GMP), which is a prerequisite for potential 
clinical use (5). These cells were shown to have stimu-
lating abilities toward adult tenocytes, along with very 
good genotypic and phenotypic stability, and the banks 
allow the availability of an off-the-shelf stock of cells 
that is easily accessible and can be rapidly used. Such 
results are promising, but to be delivered to the afflicted 
site, the cells need a support scaffold such as a matrix or 
a gel. Seeding cells within gels presents the advantage 
of being easily injectable, and as surgery is not required 
for their use, they could be particularly useful for treat-
ment of tendinopathies and simple acute injuries. The 
presence of a medium with serum or other growth fac-
tor supplement is not feasible in a preparation destined to 
be injected into the body. Therefore, we decided to work 
with formulations containing only hFPTs, phosphate-
buffered saline (PBS), and hyaluronic acid (HA) gels. 
HA is a glycosaminoglycan that is naturally present in 
numerous tissues, including tendons, and numerous gels 
based on this molecule are commercially available with 
a market authorization for injection. The variation of the 
degree of cross-linking of HA in the gel leads to charac-
teristics that can be very different, notably the viscosity 
of the gel (22). In this study, we decided to compare a 
selection of HA gels in search for one formulation that, 
on one hand, would allow for survival of hFPTs and, on 
the other hand, would have good rheological character-
istics, with the aim of creating a preparation that can be 
used for therapeutic interventions.
MATERIALS AND METHODS
Cell Culture
hFPTs were grown in a monolayer in polystyrene tissue 
culture flasks of 75 cm2 with filter screw caps (Code No. 
90076; TPP, Trasadingen, Switzerland) and were placed 
in cell culture incubators at 37°C in a humidified atmo-
sphere containing 5% CO2. They were seeded at a den-
sity of 3,000 cells/cm2 at passage 5 from a cryopreserved 
vial from our cell bank. hFPTs were isolated from the 
Achilles tendon of a male 14-week-gestation organ 
donation according to a protocol approved by the State 
Ethics Committee (University Hospital of Lausanne–
CHUV, Ethics Committee Protocol No. 62/07: 14-week-
gestation organ donation, registered under the Federal 
Transplantation Program and its Biobank complying with 
the laws and regulations). The detailed cell banking pro-
cedures were described previously (5,19). The medium 
was changed every 3 to 4 days and was composed of stan-
dard growth medium composed of Dulbecco’s modified 
Eagle’s medium (DMEM; Code No. 41966-029; Gibco, 
Life Technologies Ltd., Paisley, UK) containing 25 mM 
dextrose, 1 mM sodium pyruvate, and supplemented with 
5.97 mM L-glutamine (L-glut: Code No. 25030-024; Gibco) 
and with 10% fetal bovine serum (FBS; Code No. F7524; 
Sigma-Aldrich, St. Louis, MO, USA) without antibiotic 
supplementation. When full confluence was reached, the 
cells were detached with TrypleE (Code No. 12605-010; 
Gibco), counted with a hemocytometer, and transferred 
in desired amounts into new tubes. They were then cen-
trifuged at 250 × g, the supernatants were discarded, and 
they were rinsed twice with PBS (NaCl 6.8 g/L, Na2HPO4 
1.5 g/L, KH2PO4 0.4 g/L; Code No. 100 0 324; Bichsel, 
Interlaken, Switzerland) to eliminate all residues in the 
medium. hFPTs were then resuspended with PBS to the 
desired concentration and were ready to be used at pas-
sage 6 for the different experiments.
Comparison of Cell Survival in Commercial HA Gels
hFPT survival was evaluated in seven different commer-
cial gels containing HA in various amounts (Table 1). hFPTs 
were initially tested with a concentration of 40,000  cells 
per 100 µl of gel. A cell suspension of 4 million cells/ml 
in PBS was prepared, and 10 µl was dispatched in 9 wells 
of a 96-well plate (Code No. 3596; Corning Inc., Corning, 
NY, USA) (40,000 cells per well). There were as many 
plates prepared as conditions tested. The cells of each 
well were then resuspended with 90 µl of a specific gel 
and homogenized with a displacement pipette (Code No. 
F148504; Microman, Gilson, Middleton, WI, USA). One 
plate was evaluated directly after resuspension (0 day). 
The preservation was then evaluated at room temperature 
(RT) and at 4°C after 24 h. As the results were better at 
4°C (mean survival of 75% for 4°C compared to 66% at 
RT), other plates were prepared to test survival at the 4°C 
temperature for multiple time points (1, 2, 3, and 7 days). 
The cells did not receive any medium or growth supple-
ment during the preparation for the storage conditions. 
The survival was evaluated with a LIVE/DEAD solution 
(Code No. L-3224; Molecular Probes, Life Technologies 
Ltd., Paisley, UK). On the desired day, 100  µl of LIVE/
DEAD solution (prepared according to the manufac-
turer’s instructions) was added to the wells and mixed 
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with the displacing pipette. After 30 min of incubation at 
RT and with protection from light, images were taken with 
an inverted microscope equipped for fluorescence (IX81; 
Olympus, Tokyo, Japan) and a digital camera (iXon; Andor 
Technology Ltd., Belfast, UK). Green and red channels 
were recorded on a stack of 11 layers covering a total depth 
of 600 µm for each gel (60-µm space between slices) in the 
lower third portion. The final image was obtained within 
ImageJ (National Institutes of Health, Bethesda, MD, 
USA) through a standard deviation z-projection to obtain 
one layer composed of two color channels and converted 
to 16 bits. The final images were then analyzed with Cell 
Profiler (Broad Institute, Cambridge, MA, USA) to obtain 
the number of live and dead cells and a ratio representing 
the cell survival; calculations were done for each image. 
The identification of primary objects (live and dead cells) 
within the two color layers was done for a diameter of 10 
to 120 pixels with automatic threshold strategy and distinc-
tion of clumped objects based on the shape with dividing 
lines based on intensity. Each identification was controlled 
manually to check the accuracy of the method. The image 
processing and analysis are summarized in Figure 1. As 
there were less visible cells in some conditions, on day 7 
the bottoms of the wells were also analyzed for sedimenta-
tion, and an image was taken for each gel on a single layer 
with both colors.
Rheology on HA Gels
The dynamic viscosity of each gel was measured with a 
Rheometer System CVOR 150 CE/WIN (Bohlin Instru-
ments GmbH, Pforzheim, Germany) within a plate–plate 
system at RT. The diameter of the rotating plate was 
10 mm, the distance between the plates was 800 µm, and 
it was possible to place 80 µl of gel in between. A shear 
rate of 1 Hz was applied for 20 s of precharge, and the 
dynamic viscosity was then recorded at the same shear 
rate for 20 s and measured every 2 s. The measurements 
were then repeated twice with fresh gel. Finally, for each 
gel, the points were plotted as the mean of the three repli-
cates. The dynamic viscosity was obtained by calculating 
the mean of the 11 points obtained from the three repli-
cates, and the standard deviation was calculated on the 
basis of the same points.
Comparison of Cell Survival as a Function of Viscosity
The survival results after resuspension and after 3 days 
at 4°C are summarized in Table 2. The results are pre-
sented such that more than 85% of live cells are repre-
sented by “+++,” from 60 to 85% “++,” and for less than 
60% “+.” The degrees of viscosity are indicated in Table 2 
as follows: the gels with a viscosity higher than 50 Pas 
are represented by “+++,” from 10 to 50 Pas “++,” and 
for less than 10 Pas “+.” In parallel, a linear correlation 
was determined by plotting the survival results after 1 day 
of storage at 4°C as a function of the viscosity of the gels 
in Excel software (Microsoft, Redmond, WA, USA). The 
root mean squared error was used for the determination of 
the regression equation and the coefficient of determina-
tion (R2).
Evaluation of Cell Survival and Recovery  
With Increased Cell Concentration and 
Packaging in Syringes
The survival of hFPTs was then evaluated with 
improved formulations at a density of 500,000 cells per 
100 µl of gel and with packaging within syringes. The 
same gels as above were used, except for Hyalgan, which 
was not available for this experiment (due to supply 
problem). The cells were resuspended at a concentration 
of 50 million cells/ml in PBS, and 80 µl was dispatched 
in wells of a 48-well plate. The cells of each well were 
resuspended with 720 µl of a specific gel and homoge-
nized with a displacement pipette to reach the final con-
centration. The cell suspension was then simply aspirated 
with the syringe (without needle) to reach 500 µl, the air 
bubbles were eliminated, a cap was placed on the syringe, 
and the final preparation with 2.5 million cells in a total 
volume of 500 µl was kept at 4°C for 72 h.
The survival was evaluated with a LIVE/DEAD assay 
following a similar protocol as in the previous assay. For 
each gel, 100 µl of preparation was extruded through a 
22-gauge needle in a well of a 96-well plate, and 100 µl 
of the LIVE/DEAD solution was added. The only differ-
ence was a recording on only three layers representing 
a depth of 120 mm instead of 600 mm, as the concen-
tration was higher than previously accomplished. The 
Table 1. Selection of Commercial Hyaluronic Acid (HA) Gels
Gel Concentration in HA Manufacturer
Hyalgan 1% KELA Pharma, St-Niklaas, Belgium
Ostenil 1% TRB Chemedica, Haar, Germany
Ostenil Plus 2% TRB Chemedica, Haar, Germany
Ostenil Tendon 2% TRB Chemedica, Haar, Germany
Sinovial 0.8% 0.8% IBSA, Lodi, Italy
Sinovial 1.6% 1.6% IBSA, Lodi, Italy
Synolis V-A 2% Anteis, Plan-les-Ouates, Switzerland
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images were also taken in the lower third portion and with 
the same interspace of 60 µm between slices, as in the pre-
vious experiment.
In parallel, a recovery assay was performed in mono-
layer culture. For each gel, 100 ml was diluted to 35 ml 
of standard growth medium, and hFPTs were then dis-
patched in 12 wells of two six-well plates (evaluation of 
four time points in triplicate for each gel) with 2 ml per 
well to obtain a seeding of approximately 3,000 cells/cm2 
at passage 6 (each solution was counted to know the actual 
number of seeded cells). The plates were incubated at 
37°C and the cells were counted in three wells for each 
gel at days 4, 7, 11, and 14. The cells were rinsed with 
PBS, detached with TrypleE, and transferred to a 15-ml 
tube. The TrypleE was inactivated by the addition of an 
equal volume of medium. The cells were centrifuged at 
250 ´  g, the supernatant was discarded, and the cells were 
resuspended in an adapted volume to be counted with 
a hemocytometer. On the same days, the medium was 
replenished in the remaining wells. The population dou-
blings (PDs) were determined at each time point (equa-
tion 1), and the results were plotted as PDs as a function 
of time (PDs allow to avoid biases due to slight variations 
in seeding densities).
 
final cell number
ln
initial cell number
PD
ln(2)
 
 
 =
 
(1)
The results from hFPTs grown in six wells at passage 6 
directly from monolayer culture and which had never had 
contact with any gel were used as the control.
RESULTS
Comparison of Cell Survival in Commercial HA Gels
Figure 2 presents the cell survival of hFPTs within the 
different gels for the different conditions tested.
Directly after cell resuspension within the gel, the 
survival was determined to be excellent with Hyalgan, 
Sinovial 0.8%, and Ostenil with 94%, 93%, and 88% live 
cells, respectively. There was a weaker proportion of live 
cells within Sinovial 1.6% and Ostenil Tendon with 75% 
and 74% live cells, respectively. Finally, Synolis V-A and 
Ostenil Plus presented a relatively weak survival directly 
after resuspension with just as many cells alive as dead 
(respectively 57% and 50% live cells).
After 24 h of storage, the cell survival was better 
for every gel stored at 4°C compared to RT, except for 
Ostenil Plus. Taking the results of all gels together, the 
mean survival was 66% (ranging from 40% to 85%) at 
RT and 75% (ranging from 54% to 91%) at 4°C. Hyalgan 
presented only a limited number of visible cells after 24 h 
at RT, but no decrease in cell number was seen with the 
storage at 4°C.
After 48 h at 4°C, the survival rates followed the 
same trend as for 24-h storage at 4°C. There was again a 
decreased number of resuspended cells for Hyalgan.
After 72 h at 4°C, the same trend was seen except for 
a drop in survival for Ostenil Plus and Sinovial 0.8%. 
There was a decreased number of resuspended cells both 
for Hyalgan and Sinovial 0.8%.
After 1 week at 4°C, the survival dropped for the other 
gels, namely, Hyalgan, Ostenil, Ostenil Tendon, Sinovial 
1.6%, and Synolis V-A. The observation of the bottom 
of the wells (Fig. 3) showed that many more sedimented 
cells stayed at the bottom of the wells with Hyalgan and 
Sinovial 0.8% than with the other gels. There was also 
sedimentation with Ostenil, but to a lesser extent.
Rheology
After 20 s of precharge, the recording of the dynamic 
viscosity during 20 s was seen to be very stable and repro-
ducible between the triplicates for each gel. Hyalgan and 
Sinovial 0.8% presented very low degrees of viscosity, 
which were at 1.1 and 3.2 Pas, respectively. Ostenil and 
Sinovial 1.6% were slightly more viscous with viscosi-
ties of 11.3 and 12.2 Pas, respectively. Ostenil Plus and 
Ostenil Tendon had intermediate viscosities of 64.5 and 
60.4 Pas, respectively. Finally, Synolis V-A was the most 
viscous with 122.0 Pas (Fig. 4).
Comparison of Cell Survival as a Function of Viscosity
Table 2 summarizes the survival of hFPTs directly 
after resuspension in their respective gels and after 3 days 
of storage at 4°C alongside their degree of viscosity. 
Table 2. Summary of the Cell Survival and of the Rheology Results for the Seven Commercial HA Gels
Gel Ostenil
Ostenil 
Plus
Ostenil 
Tendon
Sinovial 
0.8%
Sinovial 
1.6%
Synolis 
V-A Hyalgan
Cell survival (resuspension) +++ + ++ +++ ++ + +++
Cell survival (conservation 3 days, 4°C) +++ + ++ ++ ++ + +++
Viscosity ++ +++ +++ + ++ +++ +
+, <60% live cells (survival), >10 Pas (viscosity).
++, 60–85% live cells (survival), 10–50 Pas (viscosity).
+++, More than 85% live cells (survival), >50 Pas (viscosity).
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Figure 2. Cell survival of hFPTs within different commercial HA gels. The images present the survival of hFPTs within HA gel for different 
conditions with various time points (0 to 7 days) and temperatures (RT or 4°C) of storage. The live cells appear in green (metabolically active), 
while the dead cells appear in red (membrane ruptured). Each image was obtained by projection of 11 slices covering a depth of 600 µm into 
one final image. The percentage indicates the ratio of live cells among the total number of cells for each image. Scale bars: 100 µm.
Figure 3. Sedimentation of hFPTs at the bottom of wells after 7 days at 4°C. After 7 days of storage, the presence of sedimented cells 
at the bottom of the wells was more pronounced in Hyalgan and Sinovial 0.8% and to a more limited degree in Ostenil. Each image 
was obtained as one single layer with both color channels. The other gels were not affected. Scale bars: 100 µm.
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Figure 5 presents hFPT survival after 24 h at 4°C as a 
function of the viscosity of the gel in which they were 
resuspended. The data follow a visible trend, and the 
coefficient of determination of the linear regression line 
is 0.84. The slope of the regression line equals −0.003, 
meaning that 0.3% of survival is lost for each supplemen-
tary unit of Pas.
Cell Survival and Recovery After 72 h at 4°C 
With Higher Cell Concentration and  
With Packaging in Syringes
After 72 h of storage at 4°C, hFPT survival at higher 
concentration in syringes ranged from 81% for Ostenil 
Plus to 94% for Sinovial 0.8% as seen with the LIVE/
DEAD experiment (Fig. 6A). Because of the high concen-
tration, the number of cells for determining survival was 
higher than in the overall gel screening experiment (mean 
of 287 cells per final image for the higher concentration 
instead of 128 cells for the lower concentration), despite a 
recording on a depth five times lower. The recovery assay 
(Fig. 6B) highlighted the fact that the cells extruded from 
all syringes were able to attach and proliferate in mono-
layer culture, and 90% to 100% confluency was reached 
after 7 days for Ostenil, Ostenil Plus, Ostenil Tendon, and 
Sinovial 0.8% and after 10 days for Sinovial 1.6% and 
Synolis V-A. The proliferation with confluency reached 
after 7 days was really close to what was found for cells 
from the same passage that were grown in monolayer 
culture and that had never been in contact with any gel 
(Fig.  6B, control).
DISCUSSION
hFPTs present very interesting characteristics in vitro 
and could be an optimal cell source for regeneration of ten-
dons (5). Nevertheless, a scaffold is required to deliver the 
cells to the wounded site, and the use of an HA gel could be 
feasible if it allows hFPTs to survive when seeded inside 
and retains flexibility for manipulation. Furthermore, with 
Figure 4. Dynamic viscosity of HA gels. The dynamic viscosity of the different commercial HA gels represents the mean of the 11 
measures made in 20 s (based on triplicates) and with the standard deviations shown as error bars.
Figure 5. Linear correlation between dynamic viscosity and hFPT survival after 1 day at 4°C. The linear correlation between the 
dynamic viscosity of the gel and the cell survival after 1 day at 4°C was very high with a coefficient of determination (R2) of 0.84. With 
a slope of −0.003, for each supplementary unit of Pas in one gel, 0.3% of survival was lost for hFPTs.
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regard to clinical application in patients, it is necessary 
to determine the stability of the cells within the gel. It is 
advantageous if the formulation can be stored for some 
time, as the delivery to operating sites can take time and 
delays in surgery schedules can occur.
First, it is important to anticipate regulatory require-
ments and to be in accordance with the laws and rec-
ommendations of the relevant government bodies and 
institutions. The HA gels tested all received a market 
authorization with the possibility to be injected. The use 
of animal-derived products such as FBS has been chal-
lenged lately, and such products were omitted in order to 
retain the potential of being injected in a clinical setting; 
hFPTs were rinsed and resuspended only with PBS before 
being mixed with an HA gel, without any medium or any 
other growth supplements. This introduces more difficul-
ties for maintaining living cells, but it is compulsory for 
the potential use of hFPTs for therapeutic intervention in 
the future.
The different experiments were conducted in an incre-
mental process, which means the techniques were adapted 
experiment after experiment. For example, once primary 
results were obtained, we changed the concentrations to 
be closer to what could be used in clinics. This explains 
why the results appear as a single replicate for an overview 
of multiple gels and why no further statistical information 
is added. However, each well was resuspended individu-
ally, and the trend for a specific gel remained the same 
throughout the time points with the same gels consistently 
presenting good survival and always the other gels con-
sistently presenting lower survival. By increasing the cell 
concentration, we obtained better survival, but the trend 
was the same among the different gels. Thus, our discus-
sion and conclusion are based on several experimental 
evaluations for each and every gel. After 24 h of storage, 
either at RT or at 4°C, the results showed that storage 
by refrigeration was better in terms of cell survival, and 
this observation could be seen for all of the gels except 
Ostenil Plus. Tendons are known to have a relatively slow 
metabolism (11,17), but tenocytes still require nutrients 
for their survival. By diminishing the temperature, the 
metabolic activity of the cells is also diminished and so 
Figure 6. Cell survival (A) and recovery (B) of hFPTs at a concentration of 500,000 cells per 100 µl in syringes after 72 h of storage 
at 4°C. (A) The live cells appear in green, while the dead cells appear in red. Each image was obtained by projection of three slices 
covering a depth of 120 µm into one final image. The percentage indicates the ratio of live cells among the total number of cells for 
each image. Scale bars: 100 µm. (B) The recovery of the cells extruded from the syringe is shown for 2 weeks of monolayer culture. 
The points represent the cumulative population doublings up to confluency. The results obtained for hFPTs that have never been in 
contact with gel and grown at the same passage were added for comparison (control).
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are their requirements. The absence of nutrients may then 
have less impact under such conditions, and this could 
explain a better survival at refrigerated temperatures up 
to a certain limit. Between day 2 and day 3, there was a 
drop in survival of more than 15% for Ostenil Plus and 
Sinovial 0.8%. The other gels underwent a similar drop 
for cell survival between day 3 and day 7. It is a major 
advantage to have a cellular preparation that can be stored 
for some time before its clinical application. It was the 
case in this study with live cells representing still 65% to 
even 89% in five gels after 3 days of conservation when 
refrigerated. This storage duration allows flexibility and 
corresponds, for example, to what is found in our hospi-
tal for other therapies, such as platelet-rich plasma (PRP) 
injections (1).
The suspension of hFPTs within Ostenil Plus and 
Synolis V-A led to negative results in terms of cell sur-
vival. This yield was found to already be decreased just 
after homogenization of the cells within gels and without 
any storage phase. These two gels presented the weakest 
proportion of live cells for each time point as expected. 
This effect was not translated into one single initial 
preparation, as the cells were resuspended for each time 
point in their individual wells. These gels were the most 
viscous of the selection, and this could probably explain 
the low overall survival even with the delicate use of dis-
placement pipettes. With increased viscosity, the shear 
stress applied on the cell surface during resuspension and 
homogenization is increased and probably leads to more 
membrane ruptures. Indeed, there was a strong linear 
correlation between cell survival after 24 h at 4°C and 
viscosity as seen by the coefficient of determination of 
0.84, and gels with a high viscosity should be carefully 
selected for resuspension of hFPTs. The negative survival 
of cells within Ostenil Plus can nevertheless not only be 
explained by the viscosity of the gel, as the survival was 
much better within Ostenil Tendon, which had a very 
similar viscosity. This implies that viscosity is probably 
not the only factor favoring cell death and indicates that 
these effects may also be due to the gel composition.
Ostenil, Sinovial 0.8%, and Hyalgan showed the best 
cell survival rates throughout the time points studied. 
These three gels presented the lowest viscosity, and it is 
probable that only a limited number of cells were dam-
aged during resuspension. The survival rates remained 
high for Hyalgan and Ostenil up to 3 days at 4°C, which 
shows a good tolerance of hFPTs for these two gels. With 
Sinovial 0.8%, there was a greater decrease in cell survival 
after 3 days of storage at 4°C, which potentially indicates 
a weaker tolerance in the long term. Despite excellent 
survival results, some other characteristics of these three 
gels, such as the fact that Hyalgan frequently presented 
less visible cells within the observed layers than in the 
other gels and that Sinovial 0.8% also did after 3 days, 
should be explored. The observation of the bottom of the 
wells after 1 week of storage at 4°C highlighted the pres-
ence of many more sedimented cells in these two gels, 
which demonstrates that a dynamic viscosity of less than 
5 Pas is insufficient to maintain the cells in suspension in 
the long term. Ostenil was subject to a lower sedimenta-
tion, and the other gels did not seem to be affected. This 
indicates that the preparation with a gel of low viscosity 
could become nonhomogenous over time, and as the final 
preparations are destined to be packaged in syringes, it 
would not be easy to resuspend the cells prior to injec-
tion. Thus, such gels could be appropriate for prepara-
tions that would be used rapidly, but not for preparations 
that would be stored. Moreover, even if the poor viscosity 
would not cause any problems for intratendinous injec-
tion, it could be responsible for leakage in the case of 
peritendinous application, for example, at the surface of 
a wounded site. Among these three gels, Ostenil seems 
the least affected by sedimentation and could be a more 
desirable candidate.
Ostenil Tendon and Sinovial 1.6% presented interme-
diate survival results, which were very close to each other. 
Sinovial 1.6%, even with a viscosity similar to standard 
Ostenil, presented a lower survival compared to this gel. 
It is likely that the negative impact on the cells is thus not 
due to shear stress during resuspension, but simply to a 
weaker tolerance of the cells toward this gel, and thus it 
would not be an ideal candidate. Despite a much higher 
viscosity, Ostenil Tendon presented a similar survival to 
Sinovial 1.6%. The survival in Ostenil Tendon was also 
much better than for Ostenil Plus, which shared a similar 
viscosity. It is probable that some cells died during the 
resuspension due to shear stress, but Ostenil Tendon did 
not seem to negatively impact the cells and seemed well 
tolerated. This gel presents an ideal compromise between 
a high rate of cell survival and an adapted viscosity for 
long-term storage and for delivery in zones where leak-
age would be a problem.
Tendinopathies are already treated with different types 
of injections; notably PRP (at a volume of 500 µl per site) 
is frequently used in our hospital. Many cell types have 
been used for tendon treatment, but the optimal number 
of cells required remains to be found (3). Based on our 
experience, we estimate that 2.5 million cells per treat-
ment would be adequate. Concentrations ranging from 
1 to 10 million cells are frequently found with stem cells 
in animal (6,8,16) and in human (13) models through in 
vivo experimentation. For these reasons, we prepared 
syringes with 2.5 million cells in 500 µl of gel in the 
second part of the study to mimic what could be used in 
clinics for the treatment of tendons. When aspirating the 
cell/gel formulations with a syringe, we used only the 
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syringe without a cannula or needle to allow the best pro-
tection of the cell preparation. However, when extrud-
ing the cells, we used a needle of 22 gauge to be similar 
to what could be used in the clinic. We did preliminary 
testing of needles from 20 to 30 gauge with very good 
results up to 23 gauge and could see a drop in survival 
with 30 gauge, with the highest impact on more viscous 
gel preparations. With other cell therapies for tendinopa-
thies using PRP, we generally used 20-gauge needles for 
direct injection into the tendon  (1).
Hyalgan was not available for this experiment (due to 
supply problems), but hFPTs were tested with all of the 
other gels, and the results were very encouraging. After 
72 h at 4°C, the survival rates presented the same trend 
to what was found in wells with a lower concentration. 
Synolis V-A and Ostenil Plus presented the lowest sur-
vival, Sinovial 0.8% had the highest survival rates, and 
the other gels were in the middle. Furthermore, the sur-
vival for each gel after 72 h of storage was much higher 
compared to the previous results with lower cell concen-
trations, and the differences between gels were lower. It is 
probable that a higher cell concentration leads to a better 
preservation during the preparation. Use of larger vol-
umes of the preparation also allowed for easier manipula-
tion and resuspension of cells.
The LIVE/DEAD assay showed that many cells main-
tained the integrity of their membrane and that they were 
still metabolically active, but it is important to note that 
they did not lose their capacity to migrate, attach, and 
proliferate. The recovery assay highlighted this fact. After 
3 days of storage at 4°C, the cells extruded from all the 
gels were able to attach to culture material and to prolifer-
ate. The cells from Ostenil, Ostenil Plus, Ostenil Tendon, 
and Sinovial 0.8% reached 90% to 100% confluency after 
7 days and presented a proliferation profile very close to 
what was found with cells at the same passage, which had 
always been grown in monolayer culture and that had not 
been in contact with any gel. There was a slight delay for 
the cells from Sinovial 1.6% and Synolis V-A, but they 
were still able to reach 90% to 100% confluency after 
10 days. These results are excellent and do not suggest 
further criteria for a discriminative choice between the 
different gels.
On the basis of the global results, Ostenil Tendon HA 
gel seems the best candidate for further development 
and for the formulation of one preparation that could be 
used therapeutically. Indeed, this gel presents a very good 
compromise between cell survival and sufficient viscos-
ity. Moreover, the recovery of cells after 3 days of storage 
at 4°C is excellent. With the off-the-shelf availability of 
hFPTs, it would be possible to prepare cell suspensions in 
this gel on demand from the clinic. The final cell prepa-
rations could be prepared under GMP along with the 
associated simple logistics to deliver them to the patient. 
Importantly, they can be stored at 4°C at least up to 72 h, 
allowing good flexibility for clinical usage.
CONCLUSION
With the view of potentially using hFPT preparations 
clinically, the use of medium, serum, or any other growth 
supplement was avoided in the preparations with HA gels. 
With such conditions, the preservation of the cell suspen-
sions in gels was improved by a refrigerated temperature, 
and it was possible to store multiple preparations up to 
3 days.
hFPTs had low survival in Synolis V-A and Ostenil 
Plus, even without storage, and these gels are thus not 
adapted for a formulation containing hFPTs. Hyalgan, 
Sinovial 0.8%, and Ostenil allowed a high degree of hFPT 
survival and could be good candidates for the preparation 
of hFPT suspensions. Because of their low viscosity, they 
are not adapted for storage and would be more suitable 
for intratendinous injection than peritendinous injection 
into a defect, where the risk of leakage would be higher. 
Ostenil Tendon and Sinovial 1.6% presented intermedi-
ate results in terms of cell survival, but as Ostenil Tendon 
viscosity is approximately five times higher than Sinovial 
1.6%, it is a more valuable choice for a formulation that 
could also be used on the surface of a wound, where a 
higher viscosity should allow a better maintenance of the 
cellular preparation. It therefore presents the best com-
promise between cell survival and adapted characteristics 
for conservation and delivery. Moreover, it is possible to 
package hFPT suspensions in syringes with 2.5 million 
cells in 500 µl of gel, which represents an adapted for-
mulation for a clinical use. With such a formulation, it is 
now possible to imagine an in vivo delivery of hFPTs to 
further evaluate and characterize this cell source.
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